Astellas Advances its Vaccine Ambitions with Affinivax’s Pneumococcal Candidate

By Jasmine Kalsi

Pharma Deals Review: Vol 2017 Issue 3 (Table of Contents)

Published: 11 Mar-2017

DOI: 10.3833/pdr.v2017.i3.2231     ISSN: 1756-7874

Section: Licensing



Looking to cutting-edge research to develop a global presence in vaccines, Astellas Pharma has in-licensed worldwide rights to a next-generation pneumococcal vaccine candidate from US-based start-up Affinivax for US$10 M upfront...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details